Author Affiliations: Departments of Neurology, AHEPA University Hospital, Thessaloniki, Greece, and Thessaly University Hospital, Larissa, Greece.
We read with considerable interest the exploratory study by Karussis et al1 on the safety of intrathecally transplanted mesenchymal stem cells (MSCs) in patients with multiple sclerosis (MS) and those with amyotrophic lateral sclerosis (ALS). Nevertheless, the data presented in that study1 do not clearly support the positive conclusion drawn, at least in MS.
Karacostas D, Hadjigeorgiou G, Ioannidis P, Milonas I. How Safe Could Intrathecal Transplantation of Mesenchymal Stem Cells Be Considered in Multiple Sclerosis?. Arch Neurol. 2011;68(7):955–956. doi:10.1001/archneurol.2011.161